SEC Company Response from CALYPTE BIOMEDICAL CORP (CIK 0000899426) — Dec 27, 2004
CALYPTE BIOMEDICAL CORP (CIK 0000899426)
Date: Dec. 27, 2004 · CIK: 0000899426 · Accession: 0001144204-04-022758
AI Filing Summary & Sentiment
File numbers found in text: 333-119646
Letter
VIA FACSIMILE AND EDGAR Securities and Exchange Commission 450 Fifth Street, NW Washington, DC 20549-0306 Attention: David Ritenour, Special Counsel
Re: Calypte Biomedical Corporation (the "Company") Amendment No. 2 to Registration Statement of Form SB-2 File No. 333-119646 Request for Acceleration -------------------------------------------------
Dear Mr. Ritenour:
The Company requests acceleration of effectiveness of the Form SB-2 Registration Statement (the "Filing") to December 29, 2004 at 5:00 P.M. Eastern Standard Time or as soon as practical thereafter.
The Company acknowledges that the disclosure in the Filing is its responsibility. The Company further acknowledges, that the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective does not relieve the Company from its full responsibility for the adequacy and accuracy of the discourses in the filing. The Company also acknowledges that in declaring the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the filing and that the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated under the federal securities laws of the United States.
Very truly yours,
CALYPTE BIOMEDICAL CORPORATION
By: /s/ Richard D. Brounstein
-------------------------
Richard Brounstein, Vice President and Chief
Financial Officer
Show Raw Text
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>
Calypte Biomedical Corporation [LOGO]
5000 Hopyard Road o Pleasanton, CA 94588
December 27, 2004
VIA FACSIMILE AND EDGAR
Securities and Exchange Commission
450 Fifth Street, NW
Washington, DC 20549-0306
Attention: David Ritenour, Special Counsel
Re: Calypte Biomedical Corporation (the "Company")
Amendment No. 2 to Registration Statement of Form
SB-2 File No. 333-119646 Request for Acceleration
-------------------------------------------------
Dear Mr. Ritenour:
The Company requests acceleration of effectiveness of the Form SB-2 Registration
Statement (the "Filing") to December 29, 2004 at 5:00 P.M. Eastern Standard Time
or as soon as practical thereafter.
The Company acknowledges that the disclosure in the Filing is its
responsibility. The Company further acknowledges, that the action of the
Commission or the staff, acting pursuant to delegated authority, in declaring
the filing effective does not relieve the Company from its full responsibility
for the adequacy and accuracy of the discourses in the filing. The Company also
acknowledges that in declaring the Registration Statement effective, it does not
foreclose the Commission from taking any action with respect to the filing and
that the Company may not assert staff comments and the declaration of
effectiveness as a defense in any proceeding initiated under the federal
securities laws of the United States.
Very truly yours,
CALYPTE BIOMEDICAL CORPORATION
By: /s/ Richard D. Brounstein
-------------------------
Richard Brounstein, Vice President and Chief
Financial Officer
Calypte Biomedical Corporation
5000 Hopyard Road, Suite 480 | Pleasanton, CA 94588
|925-730-7200 | fax 925-730-0146
</TEXT>
</DOCUMENT>